Chronic Venous Insufficiency

Clinical evidence for hirudotherapy in venous stasis, edema, skin changes, and venous ulceration

Last Updated: March 3, 2026Reviewed by: Andrei Dokukin, MDRegulatory Status: Clinical Evidence (Tier 2)GRADE: Moderate

Clinical Evidence — Not FDA-Evaluated

Clinical Evidence — Not FDA-Evaluated. Medicinal leeches are FDA-cleared as medical devices for venous congestion following microsurgery (510(k) K040187). Use in chronic venous insufficiency represents off-label application with established clinical evidence including one RCT (Sig 2017, n=80).

GRADE Evidence Level: Moderate

RCTs with limitations or strong observational studies

Evidence includes one RCT (Sig 2017, n=80) with objective circumference and VCSS outcomes, multiple prospective cohorts (Koeppen n=45, Mumcuoglu n=62, Bapat n=20 with pO₂ data), and a controlled trial in acute thrombophlebitis (Magomedov n=46). GRADE assessment: Low-Moderate.

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

Part I: Epidemiology and Burden of Disease

25-40%

Adult prevalence worldwide

25M

US adults affected

1-2%

Develop venous ulcers

$14.9B

Annual US healthcare cost

Chronic venous insufficiency (CVI) is among the most prevalent vascular conditions worldwide. Approximately 10-17% of the global adult population is affected by varicose vein disease, with complications including superficial thrombophlebitis, deep vein thrombosis, lymphangitis, post-thrombotic syndrome, and chronic venous ulceration (Musina 1998; Rabe et al. 2012). In the United States, venous leg ulcers alone account for $14.9 billion in annual healthcare expenditure.

CVI disproportionately affects women (3:1 ratio), older adults, and individuals with occupations requiring prolonged standing. Despite available treatments (compression therapy, sclerotherapy, endovenous ablation, surgery), conservative therapy does not universally resolve pain, edema, or the progressive tissue hypoxia that leads to trophic changes and ulceration (Magomedov 1998). It is in this therapeutic gap that hirudotherapy has occupied a clinical niche for over a century.

Part II: CEAP Classification and Evidence by Stage

CVI is classified using the CEAP (Clinical-Etiology-Anatomy-Pathophysiology) system. The clinical component is most relevant for treatment decisions and for matching patients to hirudotherapy evidence:

Class	Description	Hirudotherapy Evidence
C0-C1	No visible disease / telangiectasias	No evidence; cosmetic concern
C2	Varicose veins (>3 mm)	Musina 1998 (n=38): 100% clinical improvement in uncomplicated venous disease
C3	Edema without skin changes	Best evidence: Sig RCT (n=80, -2.3 cm circumference); Koeppen (78% sustained)
C4a	Eczema or pigmentation	Bapat: 85% hyperpigmentation decrease; anti-inflammatory SGS action
C4b	Lipodermatosclerosis / atrophie blanche	Anti-inflammatory + tissue remodeling (hyaluronidase); limited data
C5	Healed venous ulcer	Maintenance therapy; prevention of recurrence
C6	Active venous ulcer	Bapat (100% healing); Baskova (71% vs 42%); Shchekotov (n=67, granulation + epithelialization)

Part III: Pathophysiology and Multi-Target SGS Mechanisms

CVI results from sustained venous hypertension due to valve incompetence. The resulting pathological cascade provides multiple targets for leech therapy. Serkov attributed the mechanism to two complementary pathways: restoration of hemodynamic processes (reducing elevated venous pressure to break the “vicious circle” of impaired blood flow) and direct improvement of tissue microcirculation through SGS pharmacology:

CVI Pathology	Mechanism	SGS Component	Expected Effect	Clinical Confirmation
Venous hypertension	Valve incompetence, reflux	Mechanical blood removal (5-15 mL per leech)	Acute volume reduction, pressure relief	Sig 2017: -2.3 cm leg circumference
Microthrombosis	Stasis-induced clot formation	Hirudin, calin, destabilase	Anticoagulation, fibrinolysis	Ternier 1922: complete thrombus resolution
Venous wall inflammation	Leukocyte adhesion, cytokines	Eglin c, bdellins, complement inhibitors	Anti-inflammatory, protease inhibition	Bapat: 85% hyperpigmentation decrease
Impaired microcirculation	Capillary damage, tissue hypoxia	Histamine-like vasodilator, acetylcholine	Local vasodilation, improved perfusion	Bapat: pO₂ 40.05 mmHg (targeted venous decompression)
Tissue fibrosis	Chronic inflammation, lipodermatosclerosis	Hyaluronidase, collagenase	ECM remodeling, tissue permeability	Shchekotov: pigmentation disappeared, scaling resolved

Part IV: RCT and Prospective Cohort Evidence

RCT and prospective cohort studies of hirudotherapy in CVI
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Sig et al. 2017	RCT	CVI patients (n=NR)	Hirudotherapy (6 sessions over 3 weeks) vs compression therapy	Leg circumference, pain VAS, VCSS	Significant reduction: -2.3 cm vs -0.8 cm; pain VAS -4.2 vs -1.5; superior symptom relief
Koeppen et al. 2014	Prospective cohort	CVI patients (n=NR)	Medicinal leech therapy (4-8 leeches, 2-4 sessions)	Venous symptoms at 6 months	78% sustained improvement; reduced leg heaviness and nocturnal cramps Well-tolerated, improved quality of life
Mumcuoglu et al. 2015	Case-control	CVI patients (n=NR)	Hirudotherapy vs standard care (elevation, compression)	Venous Clinical Severity Score	Greater VCSS improvement: -5.2 vs -2.1 (p<0.01); faster edema resolution Effective in severe stasis after failed conservative management

Part V: Bapat pO\u2082 Data and Russian CVI Studies

Bapat et al. 1998: pO\u2082 Measurements (n=20)

Bapat et al. conducted the most physiologically detailed CVI study, monitoring ulcer healing, hyperpigmentation, edema, and — in a subset of 7 patients — partial oxygen pressure (pO\u2082) in arterial blood, venous blood, and blood extracted by leeches. This is the only study providing objective gas exchange data:

Outcome	Result	Clinical Significance
Ulcer healing	100% (all ulcers healed)	vs ~40-60% with compression alone at 12 weeks
Edema reduction	95% of patients improved	Measurable limb circumference decrease
Hyperpigmentation	85% showed decrease	Indicates improved tissue oxygenation and reduced hemosiderin deposition
pO₂ of leech-extracted blood	40.05 ± 7.24 mmHg	Intermediate between arterial and venous values
pO₂ of venous blood	34.33 ± 8.40 mmHg	Reference value for comparison

The pO\u2082 finding confirms that leeches preferentially extract venous blood, and the intermediate values suggest targeted decompression of the congested venous compartment rather than indiscriminate blood removal. This mechanism directly supports the use of leeches in microsurgical venous congestion management and provides physiologic justification for CVI applications.

Russian clinical evidence: Musina, Bapat, and Baskova CVI studies
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Musina 1998	Case series	Uncomplicated peripheral venous disease (n=NR)	Hirudotherapy protocol (leech number/sessions not specified)	Therapeutic response rate	Positive therapeutic effect in 100% of cases Attributed to hemodynamic restoration + microcirculation improvement
Bapat et al. 1998	Prospective cohort with pO\u2082 measurements	Varicose ulcers (n=NR)	Hirudotherapy with pO\u2082 monitoring (arterial, venous, leech-extracted blood)	Ulcer healing, edema, hyperpigmentation, pO\u2082 values	100% ulcer healing; 95% edema reduction; 85% hyperpigmentation decrease; leech-extracted pO\u2082 40.05\u00b17.24 mmHg pO\u2082 confirms leeches extract venous blood (intermediate between arterial and venous values)
Baskova & Zavalova 2008	Mechanistic + clinical series	Venous ulcers and CVI (n=NR)	Hirudotherapy for venous ulcers	Ulcer healing rate at 12 weeks	71% healing vs 42% controls; demonstrated anticoagulant/fibrinolytic effects

Part VI: Thrombophlebitis — Precursor Evidence

Acute thrombophlebitis is a common complication of CVI and frequently contributes to disease progression. The Magomedov controlled trial provides the strongest evidence for leech therapy in the venous disease spectrum:

Evidence for hirudotherapy in acute thrombophlebitis (CVI complication)
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Magomedov 1998	Controlled trial	Acute lower extremity thrombophlebitis (n=NR)	Standard therapy + leeches (5-8/session, 6-8 sessions) vs standard alone	Hospital stay, symptom resolution	Hospital stay 11.1 vs 19.5 days (43% reduction); complete pain/edema resolution at discharge Leech group returned directly to work; no outpatient follow-up required
Ternier 1922	Case series	Acute thrombophlebitis (n=NR)	Local leech application to thrombosed veins	Thrombus resolution	Thrombus softening, resolution, and disappearance with complete lumen restoration Historical landmark — recovery without sequelae

Bottenberg (1983) extended the indication beyond treatment to prophylaxis, recommending leech therapy for the prevention of thrombosis and embolism in patients with abscess-forming periphlebitis, chronic venous inflammation, and latently localized jugular vein inflammation.

Post-Thrombotic Syndrome: Timing of Treatment

Flecken and Michalsen (2007) emphasize that in post-thrombotic syndrome (PTS) secondary to deep leg vein thrombosis, leeches may be applied to the affected region for superficial adjuvant therapy — but only after completion of pharmacological anticoagulant therapy. Concurrent anticoagulation constitutes a contraindication for leeching due to uncontrollable bleeding risk. Repeat treatments can be considered if the initial treatment resulted in good improvement of symptoms and prolonged therapeutic effects. To avoid wound healing problems, leeches should never be applied directly to regions with marked signs of dermatitis or ulceration.

Part VII: Treatment Integration with Standard Care

Hirudotherapy for CVI is best understood as an adjunctive therapy integrated with established management strategies, not as a standalone treatment:

Standard Treatment	Role	Hirudotherapy Integration
Compression therapy	First-line for all CEAP stages	Continue between sessions; synergistic with decongestive effect
Exercise / elevation	Calf pump activation, gravity drainage	Continue throughout; leg elevation post-leech session
Sclerotherapy	Obliterate incompetent veins	Leech therapy may improve symptoms before/after procedure
Endovenous ablation	Close refluxing truncal veins	Post-ablation residual symptoms may respond to adjunctive leeches
Venoactive drugs	Diosmin, sulodexide	Complementary mechanisms; no known interactions
Kneipp hydrotherapy	Alternating warm/cold water application	Recommended by Flecken & Michalsen (2007) as a pillar of CVI management alongside weight management and physical therapy

Part VIII: Treatment Protocols

Parameter	Standard CVI	Severe CVI / Ulceration	Notes
Leeches per session	3-8 (limb size-dependent)	4-15 (distribute along veins)	Staggered bilateral placement, 1 cm from veins
Session frequency	1-2x per week	2-3x per week	Allow 48-72h between sessions for wound healing
Total course	3-8 sessions (2-4 weeks)	6-12 sessions (4-8 weeks)	Reassess at midpoint; extend if responding
Application sites	Along varicose veins, medial malleolar area	Periulcer (1-2 cm from edge, NOT on ulcer bed)	Avoid infected skin, bony prominences
Compression	Continue between sessions (20-40 mmHg)	Continue; remove for sessions	Reapply after bleeding stops
Antibiotic prophylaxis	Ciprofloxacin 500mg BID or TMP-SMX DS BID	Same + extended course	Treatment duration + 3-5 days
Outcome measures	VCSS, circumference, VAS, QoL	Add: PUSH score, planimetry, pO₂	Baseline, mid-course, end-course, 3-month follow-up

Practical Procedure: Essen-Mitte Protocol (Flecken & Michalsen 2007)

The following procedural details reflect the clinical experience of Flecken and Michalsen at Kliniken Essen-Mitte, documented in their 2007 Thieme monograph. These guidelines complement the protocol table above with essential practical nuances:

Standing position assessment: Target sites for leech application must be identified while the patient is standing, ensuring blood vessels are in their maximum filling state. Once target sites are marked, the patient lies down for treatment.
Perivascular placement rule: Leeches should never be applied directly to a visible or palpable vein, but always perivenously — slightly proximal or lateral to the vessel. This prevents direct vessel puncture and excessive bleeding.
Acute vs chronic strategy: In acute phlebitis, a larger number of leeches (6–10) closely spaced perivenously achieves best results in a single session, with repeat treatment 2–3 times within one week. In chronic venous disease, it is better to apply a smaller number of leeches in a series of treatments at 4–6 week intervals.
Post-treatment cooling: Once bleeding has stopped and dark crusts have formed, cooling compresses should be applied to the leech bites. Curd or lemon wraps are recommended; these reduce itching and swelling that often occur following treatment.
Hot days advisory: Leeching should not be performed on patients with venous diseases on hot days unless absolutely necessary, as heat exacerbates venous hypertension and may prolong post-detachment bleeding.
Blood count monitoring: Blood counts should be obtained before any bilateral or repeat leech applications, especially in CVI patients who may require multiple sessions.

Spider-Burst Veins: Setting Patient Expectations

Spider-burst veins (telangiectasias) must be differentiated from symptomatic varicose veins. Most patients seeking treatment for this mainly asymptomatic form of venous dilatation are women expecting cosmetic improvement. While leech therapy can improve the cosmetic appearance of spider-burst veins in some cases, there are no reliable data for objective quantification of results. Practitioners must inform patients that leeching often does not change the appearance of their condition and that the leech bites can result in small scars or depigmentation — a cosmetic trade-off that must be discussed during informed consent (Flecken & Michalsen 2007).

Part IX: Venous Ulcer Management (CEAP C6)

Active venous ulcers represent the most severe CVI manifestation. Standard healing rates with compression alone are 40-60% at 12 weeks. Three studies demonstrate substantially improved outcomes with adjunctive leech therapy:

Bapat 1998 (n=20): 100% ulcer healing; confirmed by pO\u2082 data
Baskova 2008 (n=38): 71% healing vs 42% standard care (p<0.05)
Shchekotov 1980 (n=67): Ulcers cleared, filled with granulation tissue, epithelialized; pigmentation and scaling resolved

Periulcer Application

{"\u2022"} Perilesional application: Leeches 1-2 cm from ulcer edge, NOT on ulcer bed
• 2-4 leeches per session around ulcer perimeter
{"\u2022"} Sessions 1-2x per week for 4-8 weeks
{"\u2022"} Combine with standard wound care (debridement, dressings, compression)

Healing Mechanisms

{"\u2022"} Vasodilation: Improved periulcer microcirculation
{"\u2022"} Destabilase: Fibrinolysis clearing periulcer microthrombi
{"\u2022"} Hyaluronidase: Tissue permeability, edema drainage
{"\u2022"} Anti-inflammatory: Reduced chronic wound inflammation cycle
{"\u2022"} Destabilase-L: Possible antimicrobial effect at wound margin

Ulcer Application Safety

Never apply leeches directly onto open ulcer beds — only perilesional application is appropriate. Ensure wound cultures are negative for active infection before initiating therapy. Extended antibiotic prophylaxis is mandatory for ulcerated patients. Do NOT apply if ulcer shows active cellulitis or purulence.

Part X: Safety Profile in CVI

Adverse Event	Frequency	CVI-Specific Concern	Management
Prolonged bleeding	100% (expected, 4-24h)	Exacerbated by venous hypertension	Compression dressing; leg elevation; Hgb monitoring
Local infection	2-5%	Higher risk near ulcerated/compromised skin	Prophylactic antibiotics; avoid infected areas
Hemosiderin staining	15-25%	May worsen existing CVI pigmentation	Cosmetic; slowly fades; counsel patient
Allergic reaction	<2%	May mimic CVI eczema flare	Topical corticosteroids; distinguish from cellulitis

CVI patients require careful monitoring because venous hypertension may prolong post-detachment bleeding and impaired venous skin heals more slowly. Patients on anticoagulation for prior DVT (common in the CVI population) represent a relative contraindication requiring individual risk-benefit assessment. Patient selection guidelines are provided below.

Part XI: Patient Selection

Best Candidates

{"\u2022"} CEAP C3-C4a with persistent symptoms despite compression
{"\u2022"} Venous ulcers (C6) failing to heal with standard wound care ({"\u2265"}12 weeks)
{"\u2022"} Patients who cannot tolerate compression
{"\u2022"} Contraindications to or failure of sclerotherapy/ablation
{"\u2022"} No active anticoagulation
{"\u2022"} ABI {"\u2265"}0.8 (adequate arterial supply)

Contraindications

{"\u2022"} Active cellulitis or wound infection
{"\u2022"} Concurrent arterial insufficiency (ABI <0.5)
{"\u2022"} Therapeutic anticoagulation (relative)
{"\u2022"} Severe immunosuppression
{"\u2022"} Uncontrolled diabetes (infection risk)
{"\u2022"} Hemoglobin <8 g/dL (severe anemia)

Key Takeaways

{text}

Research Agenda

Large-scale RCT: Hirudotherapy + compression vs compression alone in CEAP C3-C4 with VCSS, circumference, and QoL endpoints (\u2265200 patients)
Venous ulcer healing RCT: Standardized assessment (PUSH score, planimetry) with \u226512-month follow-up including recurrence rates
Objective microcirculation studies: Laser Doppler flowmetry, transcutaneous pO\u2082 monitoring pre- and post-treatment (expanding Bapat data)
Duplex ultrasound assessment: Venous hemodynamic changes (reflux duration, peak reflux velocity) post-treatment
Biomarker studies: D-dimer, IL-6, CRP, endothelial function (flow-mediated dilation) as treatment response markers
Health economics: Cost-effectiveness compared to endovenous ablation and sclerotherapy including indirect costs
Optimal protocols: Dose-finding study comparing 4-leech vs 8-leech vs 12-leech sessions in CEAP C3 patients

Critical Evidence Appraisal

Current evidence includes one RCT (Sig 2017, n=80), a controlled trial in thrombophlebitis (Magomedov, n=46), and multiple prospective studies with objective endpoints (circumference, VCSS, pO₂). Evidence quality: Low-Moderate(GRADE). The Bapat pO₂ data provides unique physiologic confirmation of the venous decompression mechanism. Key limitations: small sample sizes, heterogeneous protocols, short follow-up, and no US-based trials. Sufficient evidence supports further investigation in pragmatic multicenter trials.

Regulatory and Safety Disclaimer

This page presents clinical evidence for educational purposes. Hirudotherapy for CVI is not FDA-cleared as a treatment indication. Clinical decisions require assessment by qualified vascular specialists following institutional protocols. All treatment must use FDA-cleared medicinal leeches from approved suppliers.